{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:03:29Z","timestamp":1789351409482,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>While stage IIIB non-small cell lung cancer (NSCLC) is generally considered unresectable, a subset of patients may benefit from neoadjuvant therapy following comprehensive evaluation. We report a 35-year-old non-smoking female diagnosed with stage IIIB (cT1bN2bM0) adenocarcinoma of the left lower lobe with multiple-station mediastinal lymph node metastasis. Based on multidisciplinary evaluation of multimodality imaging and ALK-positive status, the patient with high tumor burden yet no significant comorbidities received neoadjuvant lorlatinib. The patient achieved a complete metabolic response (CMR) on restaging PET-CT after 10 weeks of lorlatinib, which led to a multidisciplinary decision to undergo uniportal VATS lobectomy. Pathological examination confirmed a pathological complete response (pCR). After an uneventful 5-day hospitalization without complications, the patient remains disease-free at the 12-month follow-up. This is the first report of neoadjuvant lorlatinib followed by uniportal VATS achieving pCR predicted by CMR in stage IIIB ALK-positive NSCLC, given the limitations of short-term follow-up and a single-case design.<\/jats:p>","DOI":"10.1186\/s13019-026-04405-1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T20:04:46Z","timestamp":1782677086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From metabolic to pathologic complete response: case report of Neoadjuvant Lorlatinib in Stage IIIB ALK-positive NSCLC combined with uniportal VATS"],"prefix":"10.1186","volume":"21","author":[{"given":"Ruifeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chudong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuben","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"1","key":"4405_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","volume":"44","author":"D Miao","year":"2024","unstructured":"Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, et al. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 2024;44(1):23\u201346.","journal-title":"Cancer Commun (Lond)"},{"issue":"4","key":"4405_CR2","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jtho.2020.12.021","volume":"16","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka M, Ou SI. Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. J Thorac Oncol. 2021;16(4):532\u20136.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"4405_CR3","first-page":"403","volume":"2","author":"Y Liang","year":"2013","unstructured":"Liang Y, Wakelee HA. Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2013;2(5):403\u201310.","journal-title":"Transl Lung Cancer Res"},{"issue":"29","key":"4405_CR4","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024;42(29):3400\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4405_CR5","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtho.2025.02.021","volume":"20","author":"YL Wu","year":"2025","unstructured":"Wu YL, Kim HR, Soo RA, Zhou Q, Akamatsu H, Chang GC, et al. First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study. J Thorac Oncol. 2025;20(7):955\u201368.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4405_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354\u201366.","journal-title":"Lancet Respir Med"},{"key":"4405_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2023.02.001","volume":"178","author":"F Zhuang","year":"2023","unstructured":"Zhuang F, Haoran E, Huang J, Wu J, Xu L, Zhang L, et al. Utility of (18)F-FDG PET\/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. Lung Cancer. 2023;178:20\u20137.","journal-title":"Lung Cancer"},{"key":"4405_CR8","doi-asserted-by":"crossref","unstructured":"Seitlinger J, Salko O, Bulgarelli Maqueda L, Meng A, T\u00eatu M, Desilets A, et al. Neoadjuvant Chemotherapy-Immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography Scan Predict Complete Pathologic Response? Ann Thorac Surg. 2026;121(6):1347\u201355.","DOI":"10.1016\/j.athoracsur.2025.09.051"},{"key":"4405_CR9","doi-asserted-by":"crossref","unstructured":"He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, et al. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. J Clin Oncol. 2025;43(26):2875\u201387.","DOI":"10.1200\/JCO-25-00883"},{"issue":"8","key":"4405_CR10","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00262-021-02847-1","volume":"70","author":"L Jiang","year":"2021","unstructured":"Jiang L, Huang J, Jiang S, Rong W, Shen Y, Li C, et al. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer. Cancer Immunol Immunother. 2021;70(8):2313\u201321.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04405-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04405-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04405-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:38:36Z","timestamp":1789349916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13019-026-04405-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4405"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-04405-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8711384\/v1","asserted-by":"object"}]},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We obtained comprehensive informed consent from the patient. Ethical approval for this case report was waived by the Ethics Committee of The First Affiliated Hospital of Guangzhou Medical University.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the author and the patient have consent for the publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"698"}}